Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination.
Hoffmann M, Hofmann-Winkler H, Krüger N, Kempf A, Nehlmeier I, Graichen L, Arora P, Sidarovich A, Moldenhauer AS, Winkler MS, Schulz S, Jäck HM, Stankov MV, Behrens GMN, Pöhlmann S. Hoffmann M, et al. Among authors: sidarovich a. Cell Rep. 2021 Jul 20;36(3):109415. doi: 10.1016/j.celrep.2021.109415. Epub 2021 Jun 29. Cell Rep. 2021. PMID: 34270919 Free PMC article.
B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination.
Arora P, Sidarovich A, Krüger N, Kempf A, Nehlmeier I, Graichen L, Moldenhauer AS, Winkler MS, Schulz S, Jäck HM, Stankov MV, Behrens GMN, Pöhlmann S, Hoffmann M. Arora P, et al. Among authors: sidarovich a. Cell Rep. 2021 Oct 12;37(2):109825. doi: 10.1016/j.celrep.2021.109825. Epub 2021 Sep 28. Cell Rep. 2021. PMID: 34614392 Free PMC article.
Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance.
Arora P, Kempf A, Nehlmeier I, Graichen L, Sidarovich A, Winkler MS, Schulz S, Jäck HM, Stankov MV, Behrens GMN, Pöhlmann S, Hoffmann M. Arora P, et al. Among authors: sidarovich a. Cell Mol Immunol. 2021 Nov;18(11):2557-2559. doi: 10.1038/s41423-021-00772-y. Epub 2021 Oct 11. Cell Mol Immunol. 2021. PMID: 34635807 Free PMC article. No abstract available.
Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3.
Arora P, Zhang L, Rocha C, Sidarovich A, Kempf A, Schulz S, Cossmann A, Manger B, Baier E, Tampe B, Moerer O, Dickel S, Dopfer-Jablonka A, Jäck HM, Behrens GMN, Winkler MS, Pöhlmann S, Hoffmann M. Arora P, et al. Among authors: sidarovich a. Lancet Infect Dis. 2022 Jun;22(6):766-767. doi: 10.1016/S1473-3099(22)00224-9. Epub 2022 Apr 12. Lancet Infect Dis. 2022. PMID: 35427493 Free PMC article. No abstract available.
Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy.
Hoffmann M, Sidarovich A, Arora P, Krüger N, Nehlmeier I, Kempf A, Graichen L, Winkler MS, Niemeyer D, Goffinet C, Drosten C, Schulz S, Jäck HM, Pöhlmann S. Hoffmann M, et al. Among authors: sidarovich a. mBio. 2022 Jun 28;13(3):e0036422. doi: 10.1128/mbio.00364-22. Epub 2022 Apr 25. mBio. 2022. PMID: 35467423 Free PMC article.
SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies.
Arora P, Zhang L, Krüger N, Rocha C, Sidarovich A, Schulz S, Kempf A, Graichen L, Moldenhauer AS, Cossmann A, Dopfer-Jablonka A, Behrens GMN, Jäck HM, Pöhlmann S, Hoffmann M. Arora P, et al. Among authors: sidarovich a. Cell Host Microbe. 2022 Aug 10;30(8):1103-1111.e6. doi: 10.1016/j.chom.2022.04.017. Epub 2022 May 6. Cell Host Microbe. 2022. PMID: 35588741 Free PMC article.